Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 14/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | RHEB | Q15382 | 1/20 | 0.31 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1278451 | 1.00 | HTR2A (0.40) | HTR2ASLC6A4KCNH2ARBRAF | |
| SCHEMBL29427853 | 1.00 | HTR2A (0.40) | HTR2ASLC6A4KCNH2ARBRAF | |
| SCHEMBL119682 | 1.00 | HTR2A (0.40) | HTR2ASLC6A4KCNH2ARBRAF | |
| SCHEMBL374922 | 0.95 | HTR2A (0.37) | HTR2ASLC6A4KCNH2AR | |
| SCHEMBL12710235 | 0.92 | HTR2A (0.32) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL12710204 | 0.91 | RHEB (0.35) | HTR2ASLC6A4KCNH2ARRHEB | |
| SCHEMBL28347300 | 0.90 | HTR2A (0.41) | HTR2ASLC6A4KCNH2ARBRAF | |
| SCHEMBL912518 | 0.90 | HTR2A (0.37) | HTR2ASLC6A4KCNH2ARSCN9A | |
| SCHEMBL912517 | 0.90 | HTR2A (0.37) | HTR2ASLC6A4KCNH2ARSCN9A | |
| SCHEMBL121354 | 0.88 | SCN9A (0.38) | HTR2ASLC6A4KCNH2ARBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562569-B1 | ANTIFUNGAL MEDICAMENTS COMPRISING ARYLAMIDINE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2009-12-23 | — | — | EP | claimed |
| US-20060052459-A1 | Antifungal medicaments comprising arylamidine derivatives | BAYER SAS (FR) | 2006-03-09 | — | — | US | claimed |
| US-6893650-B1 | N2-phenylamidine derivatives | BAYER CROPSCIENCE GMBH (DE) | 2005-05-17 | — | — | US | claimed |
| EP-1413301-A1 | Antifungal medicaments comprising arylamidine derivatives | Bayer CropScience SA (FR) | 2004-04-28 | — | — | EP | claimed |
| EP-1562569-B1 | ANTIFUNGAL MEDICAMENTS COMPRISING ARYLAMIDINE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2009-12-23 | — | — | EP | disclosed |
| US-20060052459-A1 | Antifungal medicaments comprising arylamidine derivatives | BAYER SAS (FR) | 2006-03-09 | — | — | US | disclosed |
| EP-1413301-A1 | Antifungal medicaments comprising arylamidine derivatives | Bayer CropScience SA (FR) | 2004-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052459-A1 | Antifungal medicaments comprising arylamidine derivatives | DPM1, MAN2B1, MANBA | HTR2A 1839/4885SLC6A4 732/4885KCNH2 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.